Jusqu'où aller dans la désescalade thérapeutique en radiothérapie du cancer du sein infiltrant ?

Christophe Hennequin; Sophie Guillerm; Laurent Quero

doi:10.1016/S0007-4551(16)30153-9

Jusqu'où aller dans la désescalade thérapeutique en radiothérapie du cancer du sein infiltrant ?

Bull Cancer. 2016 Jun;103(6 Suppl 1):S99-S104. doi: 10.1016/S0007-4551(16)30153-9.

[Article in French]

Authors

Christophe Hennequin¹, Sophie Guillerm², Laurent Quero²

Affiliations

¹ Service de cancérologie-radiothérapie, Hôpital Saint-Louis, Paris. Electronic address: christophe.hennequin2@aphp.fr.
² Service de cancérologie-radiothérapie, Hôpital Saint-Louis, Paris.

PMID: 27494982
DOI: 10.1016/S0007-4551(16)30153-9

Abstract

WHERE CAN WE GO?: Adjuvant radiotherapy (RT) has an important role in the management of infiltrating breast cancer, not only to improve local control but also overall survival. So, all attempt of de-escalation must be performed in the context of large prospective studies. However, RT could induce some complications and last 5 to 7 weeks. Three ways of RT de-escalation have been studied.

Keywords: Breast cancer; Cancer du sein; Intra-operative; Irradiation partielle; Irradiation per-opératoire; Partial breast irradiation; Radiotherapy; Radiothérapie; irradiation.

Publication types

Editorial

MeSH terms

Brachytherapy
Breast Neoplasms / pathology
Breast Neoplasms / radiotherapy*
Carcinoma, Ductal, Breast / pathology
Carcinoma, Ductal, Breast / radiotherapy*
Female
Humans
Lymphatic Irradiation
Radiation Dose Hypofractionation
Radiotherapy / adverse effects
Radiotherapy, Adjuvant